Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0TU5W
|
||||
| Former ID |
DNC003543
|
||||
| Drug Name |
4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [534802] | ||
| Formula |
C19H20ClN3
|
||||
| Canonical SMILES |
C1CN(CCN1CC2=CC=CC=C2)C3=C(C=CC4=C3C=CN4)Cl
|
||||
| InChI |
1S/C19H20ClN3/c20-17-6-7-18-16(8-9-21-18)19(17)23-12-10-22(11-13-23)14-15-4-2-1-3-5-15/h1-9,21H,10-14H2
|
||||
| InChIKey |
IRFLVVGRMBDQSJ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | D(3) dopamine receptor | Target Info | Inhibitor | [534802] | |
| D(4) dopamine receptor | Target Info | Inhibitor | [534802] | ||
| D(2) dopamine receptor | Target Info | Inhibitor | [534802] | ||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.